SIOC 中文
CJOG
Adv search

Chinese Journal of Organic Chemistry >

2024 , Vol. 44 >Issue 11: 3550 - 3555

DOI: https://doi.org/10.6023/cjoc202403009

NOTE

Convergent Strategy to Synthesize (S)-8-(4-((1-(3-Fluoropropyl)-pyrrolidin-3-yl)oxy)phenyl)-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol as a Selective Estrogen Receptor Degrader

  • Panpan Chen ,
  • Xiaowei Feng ,
  • Zhipeng Lu ,
  • Tingyou Li
Expand
  • a Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing 211166
    b Department of Medicinal Chemistry, School of Pharmacy, Nanjing Medical University, Nanjing 211166
*Corresponding author. E-mail:

Received date: 2024-03-06

  Revised date: 2024-05-21

  Online published: 2024-06-24

Supported by

Science and Technology Development Foundation of Nanjing Medical University(NMUB20210013); Key Project of Connotation Construction of Nanjing Medical University; China Postdoctoral Science Foundation(2022M711419); Natural Science Foundation of Jiangsu Province(BK20231266)

Fold

Abstract

A more feasibly convergent synthesis of selective estrogen receptor degrading agent (S)-8-(4-((1-(3-fluoropropyl)- pyrrolidin-3-yl)oxy)phenyl)-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol was reported, featured with concise work up and absence of regioselectivity dilemma.

Key words： breast cancer; selective estrogen receptor degrading agent; (S)-8-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)- phenyl)-7-(4 -hydroxyphenyl)-5,6-dihydronaphthalen-2-ol; improvement of synthesis

Cite this article

Panpan Chen , Xiaowei Feng , Zhipeng Lu , Tingyou Li . Convergent Strategy to Synthesize (S)-8-(4-((1-(3-Fluoropropyl)-pyrrolidin-3-yl)oxy)phenyl)-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol as a Selective Estrogen Receptor Degrader[J]. Chinese Journal of Organic Chemistry, 2024 , 44(11) : 3550 -3555 . DOI: 10.6023/cjoc202403009

References

[1]
Sung H.; Ferlay J.; Siegel R.; Laversanne M.; Soerjomataram I.; Jemal A.; Freddie Bray F. Ca-Cancer J. Clin. 2021, 71, 209.
[2]
Tang J.; Wu Z.; Tian Z.; Chen W.; Wu G. Cell Death Discovery 2021, 12, 534.
[3]
Huang B.; Omoto Y.; Iwase H.; Yamashita H.; Toyama T.; Coombes R.; Filipovic A.; Warner M.; Gustafsson J. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 1933.
[4]
Burstein H. N. Engl. J. Med. 2020, 383, 2557.
[5]
Jin M.; Yang L.; Jeong K. Theranostics 2022, 12, 5761.
[6]
Ma C.; Reinert T.; Chmielewska I.; Ellis M. Nat. Rev. Cancer 2015, 15, 261.
[7]
Osborne C.; Pippen J.; Jones S.; Parker L.; Ellis M.; Come S.; Gertler S.; May J.; Burton G.; Dimery I.; Webster A.; Morris C.; Elledge R.; Buzdar A. J. Clin. Oncol. 2002, 20, 3386.
[8]
Wakeling A.; Dukes M.; Bowler J. Cancer. Res 1991, 51, 3867.
[9]
Kruchten M.; de Vries E.; Glaudemans A.; van Lanschot M.; van Faassen M.; Kema I.; Brown M.; Schr?der C.; de Vries E.; Hospers G. Cancer Discovery 2015, 5, 72.
[10]
El-Ahmad Y.; Tabart M.; Halley F.; Certal V.; Thompson F.; Filoche-Rommé B.; Gruss-Leleu F.; Muller C.; Brollo M.; Fabien L.; Loyau V.; Bertin L.; Richepin P.; Pilorge F.; Desmazeau P.; Girardet C.; Beccari S.; Louboutin A.; Lebourg G.; Le-Roux J.; Terrier C.; Vallée F.; Steier V.; Mathieu M.; Rak A.; Abecassis P.; Vicat P.; Benard T.; Bouaboula M.; Sun F.; Shomali M.; Hebert A.; Levit M.; Cheng H.; Courjaud A.; Ginesty C.; Perrault C.; Garcia-Echeverria C.; McCort G.; Schio L. J. Med. Chem. 2020, 63, 512.
Options
Outlines

/

〈 〉